0.05Open0.03Pre Close10 Volume42 Open Interest7.50Strike Price50.00Turnover115.04%IV57.95%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0863Delta0.1113Gamma95.60Leverage Ratio-0.0046Theta0.0002Rho8.25Eff Leverage0.0019Vega
Capricor Therapeutics Stock Discussion
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Liquidia(LQDA.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$MorphoSys(MOR.US)$ Phase 3
$Immunocore(IMCR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$Capricor Therapeutics(CAPR.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3 ...
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
No comment yet